179 related articles for article (PubMed ID: 34380638)
1. The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8.
Filipits M; Rudas M; Kainz V; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Regitnig P; Halper S; Hulla W; Egle D; Barron S; Loughman T; O'Leary D; Gallagher WM; Hlauschek D; Gnant M; Dubsky P
Clin Cancer Res; 2021 Nov; 27(21):5931-5938. PubMed ID: 34380638
[TBL] [Abstract][Full Text] [Related]
2. Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
Buus R; Sestak I; Barron S; Loughman T; Fender B; Ruiz CL; Dynoodt P; Wang CA; O'Leary D; Gallagher WM; Dowsett M; Cuzick J
Clin Cancer Res; 2020 Feb; 26(3):623-631. PubMed ID: 31641007
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
Lynch SM; Russell NM; Barron S; Wang CA; Loughman T; Dynoodt P; Fender B; Lopez-Ruiz C; O'Grady A; Sheehan KM; Fay J; Amberger-Murphy V; Saha A; Klinger R; Gonzalez CA; Al-Attar N; Rahman A; O'Leary D; Lanigan FT; Bracken AP; Crown J; Kelly CM; O'Connor DP; Gallagher WM
Eur J Cancer; 2021 Jul; 152():78-89. PubMed ID: 34090143
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
[TBL] [Abstract][Full Text] [Related]
5. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Gnant M; Filipits M; Greil R; Stoeger H; Rudas M; Bago-Horvath Z; Mlineritsch B; Kwasny W; Knauer M; Singer C; Jakesz R; Dubsky P; Fitzal F; Bartsch R; Steger G; Balic M; Ressler S; Cowens JW; Storhoff J; Ferree S; Schaper C; Liu S; Fesl C; Nielsen TO;
Ann Oncol; 2014 Feb; 25(2):339-45. PubMed ID: 24347518
[TBL] [Abstract][Full Text] [Related]
6. PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
Fitzal F; Filipits M; Fesl C; Rudas M; Greil R; Balic M; Moinfar F; Herz W; Dubsky P; Bartsch R; Ferree S; Schaper C; Gnant M;
Br J Surg; 2021 Apr; 108(3):308-314. PubMed ID: 33608712
[TBL] [Abstract][Full Text] [Related]
7. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
Gnant M; Sestak I; Filipits M; Dowsett M; Balic M; Lopez-Knowles E; Greil R; Dubsky P; Stoeger H; Rudas M; Jakesz R; Ferree S; Cowens JW; Nielsen T; Schaper C; Fesl C; Cuzick J
Ann Oncol; 2015 Aug; 26(8):1685-91. PubMed ID: 25935792
[TBL] [Abstract][Full Text] [Related]
8. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Sgroi DC; Sestak I; Cuzick J; Zhang Y; Schnabel CA; Schroeder B; Erlander MG; Dunbier A; Sidhu K; Lopez-Knowles E; Goss PE; Dowsett M
Lancet Oncol; 2013 Oct; 14(11):1067-1076. PubMed ID: 24035531
[TBL] [Abstract][Full Text] [Related]
9. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Martin M; Brase JC; Calvo L; Krappmann K; Ruiz-Borrego M; Fisch K; Ruiz A; Weber KE; Munarriz B; Petry C; Rodriguez CA; Kronenwett R; Crespo C; Alba E; Carrasco E; Casas M; Caballero R; Rodriguez-Lescure A
Breast Cancer Res; 2014 Apr; 16(2):R38. PubMed ID: 24725534
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer.
Sestak I; Filipits M; Buus R; Rudas M; Balic M; Knauer M; Kronenwett R; Fitzal F; Cuzick J; Gnant M; Greil R; Dowsett M; Dubsky P
Clin Cancer Res; 2020 Sep; 26(17):4682-4687. PubMed ID: 32561662
[TBL] [Abstract][Full Text] [Related]
11. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Buus R; Sestak I; Kronenwett R; Denkert C; Dubsky P; Krappmann K; Scheer M; Petry C; Cuzick J; Dowsett M
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27400969
[TBL] [Abstract][Full Text] [Related]
12. Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
Sestak I; Zhang Y; Schroeder BE; Schnabel CA; Dowsett M; Cuzick J; Sgroi D
Clin Cancer Res; 2016 Oct; 22(20):5043-5048. PubMed ID: 27252417
[TBL] [Abstract][Full Text] [Related]
13. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Dowsett M; Cuzick J; Wale C; Forbes J; Mallon EA; Salter J; Quinn E; Dunbier A; Baum M; Buzdar A; Howell A; Bugarini R; Baehner FL; Shak S
J Clin Oncol; 2010 Apr; 28(11):1829-34. PubMed ID: 20212256
[TBL] [Abstract][Full Text] [Related]
14. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
[TBL] [Abstract][Full Text] [Related]
15. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Filipits M; Rudas M; Jakesz R; Dubsky P; Fitzal F; Singer CF; Dietze O; Greil R; Jelen A; Sevelda P; Freibauer C; Müller V; Jänicke F; Schmidt M; Kölbl H; Rody A; Kaufmann M; Schroth W; Brauch H; Schwab M; Fritz P; Weber KE; Feder IS; Hennig G; Kronenwett R; Gehrmann M; Gnant M;
Clin Cancer Res; 2011 Sep; 17(18):6012-20. PubMed ID: 21807638
[TBL] [Abstract][Full Text] [Related]
16. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
[TBL] [Abstract][Full Text] [Related]
17. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Dowsett M; Sestak I; Lopez-Knowles E; Sidhu K; Dunbier AK; Cowens JW; Ferree S; Storhoff J; Schaper C; Cuzick J
J Clin Oncol; 2013 Aug; 31(22):2783-90. PubMed ID: 23816962
[TBL] [Abstract][Full Text] [Related]
18. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
19. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.
Sestak I; Cuzick J; Dowsett M; Lopez-Knowles E; Filipits M; Dubsky P; Cowens JW; Ferree S; Schaper C; Fesl C; Gnant M
J Clin Oncol; 2015 Mar; 33(8):916-22. PubMed ID: 25332252
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
